AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
303.26B
Market cap303.26B
Price-Earnings ratio
28.56
Price-Earnings ratio28.56
Dividend yield
1.67%
Dividend yield1.67%
Average volume
1.80M
Average volume1.80M
High today
$194.64
High today$194.64
Low today
$192.24
Low today$192.24
Open price
$194.01
Open price$194.01
Volume
2.11M
Volume2.11M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$122.48
52 Week low$122.48

Stock Snapshot

With a market cap of 303.26B, AstraZeneca(AZN) trades at $193.50. The stock has a price-to-earnings ratio of 28.56 and currently yields dividends of 1.7%.

On 2026-03-30, AstraZeneca(AZN) stock moved within a range of $192.24 to $194.64. With shares now at $193.50, the stock is trading +0.7% above its intraday low and -0.6% below the session's peak.

Trading volume for AstraZeneca(AZN) stock has reached 2.11M, versus its average volume of 1.8M.

The stock's 52-week range extends from a low of $122.48 to a high of $212.71.

The stock's 52-week range extends from a low of $122.48 to a high of $212.71.

AZN News

24/7 Wall St. 12h
Guggenheim Raises AstraZeneca Price Target Ahead of Q1 Earnings

Guggenheim Raises AstraZeneca Price Target Ahead of Q1 Earnings By Joel South Published Mar 30, 9:58AM EDT Quick Read AstraZeneca (AZN) reported FY2025 revenu...

Guggenheim Raises AstraZeneca Price Target Ahead of Q1 Earnings
TipRanks 1d
Jacobio Secures US$100 Million Upfront From AstraZeneca for Pan-KRAS Cancer Drug

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Simply Wall St 3d
AstraZeneca COPD Success Tests Regeneron Dupixent Growth Story

AstraZeneca reported that its antibody drug tozorakimab succeeded in two Phase 3 trials in chronic obstructive pulmonary disease (COPD), targeting a broad COPD...

AstraZeneca COPD Success Tests Regeneron Dupixent Growth Story

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
12.9%
Sell
6.5%

More AZN News

TipRanks 3d
AstraZeneca Expands DNA-Repair Oncology Pipeline With New AZD4956 Combination Trial

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca (AZN) is running a new early-stage cancer trial called “A Modular Ope...

The Wall Street Journal 3d
AstraZeneca Shares Surge on COPD Trial Success

AstraZeneca shares were up about 3.5% Friday after the company said its drug for COPD, a deadly lung disease often caused by smoking, slowed patients' symptoms...

AstraZeneca Shares Surge on COPD Trial Success
Nasdaq 3d
AstraZeneca Stock Rises 4% Over Positive Data From Tozorakimab Study

(RTTNews) - Shares of AstraZeneca PLC (AZN) are gaining about 4 percent on Friday morning trading after the company announced positive high-level results from t...

AstraZeneca Stock Rises 4% Over Positive Data From Tozorakimab Study
Benzinga 4d
AstraZeneca Strengthens Position In COPD Race With Successful Trials

Positive COPD Data Tozorakimab is a monoclonal antibody targeting interleukin-33 (IL-33), which inhibits the signalling of the reduced and oxidised forms of IL...

AstraZeneca Strengthens Position In COPD Race With Successful Trials
TipRanks 4d
AstraZeneca Stock Soars after Successful $5B Lung Disease Treatment Trial

Shares in drug giant AstraZeneca (AZN) were looking healthier today after it hailed the success of an experimental drug to treat a chronic lung disease. Claim 3...

TipRanks 5d
Keymed Biosciences boosts revenue on Kangyueda push while deepening R&D pipeline

Keymed Biosciences, Inc. ( (HK:2162) ) has issued an announcement. Keymed Biosciences reported 2025 revenue of RMB716.3 million, up 67% year on year, with gros...

TipRanks 5d
AstraZeneca Completes Heart Failure Wearable Study, Boosting Its Digital Health Edge

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The study, titled “Clinical Observational Study of Remote, Non-invasive, Multidomain E...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.